drugset / Trial / NCT05341193
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Phase 1/2
Unknown
32 enrolled
Sun Yat-sen University
The First Affiliated Hospital of Nanchang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment regimen". Considering the synergistic effect among radiotherapy, immunotherapy and anti-angiogenesis therapy, we chose PD-1 inhibitor combined with bevacizumab to replace cisplatin chemotherapy.
Timeline
- Start
- 2022-04-30
- Primary completion
- 2023-04-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |